EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer
EUS-guided Intratumoral Gemcitabine Therapy in Locally Advanced Unresectable Pancreatic Cancer: A Phase 1 Study
Pancreatic cancer is the 11th most common type of cancer but it is the fourth leading cause of cancer death. The only effective treatment for pancreatic cancer includes surgery. However, only 20% of the patients have surgically treatable disease. Also, the 5-year survival for the surgically treated patients is only 15%.
About 40% of the patients present with advanced disease with distant metastasis, and the remaining 40% present with locally advanced unresectable cancer with the tumor invaded into surrounding major vessels. For those with locally advanced disease, systemic chemotherapy with or without radiotherapy provides palliation of the symptoms but cannot cure the disorder. Systemic chemotherapy is given through peripheral vessels.
The investigators hypothesized that direct injection of the chemotherapeutic drug into the tumor may help to boost the effect of systemic chemotherapy and radiotherapy in those with locally advanced pancreatic cancer.
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Tehran、伊朗伊斯兰共和国
- Digestive Disease Research Center, Shariati ospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients with histologically verified pancreatic adenocarcinoma who have locally advanced unresectable tumor
Exclusion Criteria:
- Early stage resectable pancreatic cancer with the intact surrounding major vessels on imaging
- Pancreatic cancer with distant metastasis
- Unwilling to sign informed consent
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Intratumoral gemcitabine injection
Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
|
Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3. The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
将不良事件作为安全性和耐受性衡量标准的参与者人数
大体时间:6个月
|
6个月
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Proportion of participants who remain alive one year after enrollment compared to the historical matched control group
大体时间:1 year
|
1 year
|
合作者和调查者
调查人员
- 首席研究员:Mehdi Mohamadnejad, M.D.、Digestive Disease Research Center, University of Tehran/Medical Sciences
- 学习椅:Reza Malekzadeh, M.D.、Digestive Disease Research Center, University of Tehran/Medical Sciences
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Gemcitabine的临床试验
-
Fondazione Policlinico Universitario Agostino Gemelli...招聘中